ELISA/assay

Rat apoprotein A1 ELISA Kit

MBS723961

48-Strip-Wells

470 USD

ELISA Kit

Rat apoprotein A1 ELISA Kit

apoprotein A1

Rat apoprotein A1 ELISA Kit; apoprotein A1; apoprotein A1 (Rat)

apolipoprotein A-I preproprotein; Apolipoprotein A-I; apolipoprotein A-I; apo-AI; apoA-I; OTTHUMP00000043268; OTTHUMP00000069346; OTTHUMP00000069347; OTTHUMP00000069348; apolipoprotein A-I; Apolipoprotein A1

Apo-A1

APOA1; APOA1; MGC117399

APOA1_HUMAN

Rat

This assay has high sensitivity and excellent specificity for detection of AP-A1. No significant cross-reactivity or interference between AP-A1 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between AP-A1 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This AP-A1 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Rat AP-A1. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Rat ELISA Kit

Principle of the Assay: AP-A1 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-AP-A1 antibody and an AP-A1-HRP conjugate. The assay sample and buffer are incubated together with AP-A1-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the AP-A1 concentration since AP-A1 from samples and AP-A1-HRP conjugate compete for the anti-AP-A1 antibody binding site. Since the number of sites is limited, as more sites are occupied by AP-A1 from the sample, fewer sites are left to bind AP-A1-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The AP-A1 concentration in each sample is interpolated from this standard curve.

4557321

NP_000030.1

NM_000039.1

P02647

30,778 Da

ABC-family Proteins Mediated Transport Pathway (106573); African Trypanosomiasis Pathway (194384); African Trypanosomiasis Pathway (194323); Amyloids Pathway (366238); Chylomicron-mediated Lipid Transport Pathway (106157); FOXA2 And FOXA3 Transcription Factor Networks Pathway (137911); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Fatty Acid, Triacylglycerol, And Ketone Body Metabolism Pathway (160977); Folate Metabolism Pathway (198833)

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. [provided by RefSeq]

Function: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. Ref.20. Subunit structure: Interacts with APOA1BP and CLU. Component of a sperm activating protein complex (SPAP), consisting of APOA1, an immunoglobulin heavy chain, an immunoglobulin light chain and albumin. Ref.25 Ref.31. Subcellular location: Secreted. Tissue specificity: Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. Ref.33. Post-translational modification: Palmitoylated. Ref.28Phosphorylation sites are present in the extracelllular medium. Involvement in disease: Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [. MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant. Ref.37 Ref.38Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [. MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I. Ref.37 Ref.38Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [. MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed. Ref.37 Ref.38 Ref.43 Ref.44Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [. MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. Ref.37 Ref.38 Ref.46. Sequence similarities: Belongs to the apolipoprotein A1/A4/E family.

48-Strip-Wells

470 USD

96-Strip-Wells

675